in non-small cell lung cancer confers significant stage-independent survival dis- Expression of novel molecules

 W. Zhou, et al. Cancer Letters 483 (2020) 75–86 [35] 2016Alzheimer\'sdiseasefactsandfigures.AlzheimersDement.12(2016)459-509. Hernandez, PTENand PI3K/AKT in non-small-cell lung cancer, Pharmacogenomics [36] M. Reck, D.F. Heigener, T. Mok, J.C. Soria, K.F. Rabe, Management of non-small- 16 (2015) 1843–1862. cell lung cancer: recent developments, Lancet 382 (2013) 709–719. [45] O.David,H.LeBeau,A.R.Brody,M.Friedman,J.Jett,Phospho-Aktoverexpression [37] S. Ashida, M. Furihata, T. Katagiri, K. Tamura, Y. Anazawa, H. Yoshioka, et al., in non-small cell lung cancer confers significant stage-independent survival dis- Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), in- advantage, Chest 125 (2004) 152S. creaseswithhighGleasonscoreandprostatecancerprogression,Clin.Canc.Res.12 [46] S.Wang,Y.Zheng,Z.He,W.Zhou,Y.Cheng,C.Zhang,SH2B1promotesNSCLCcell (2006) 2767–2773. proliferation through PI3K/Akt/mTOR signaling cascade, Canc. Cell Int. 18 (2018) [38] E.Psichari,A.Balmain,D.Plows,V.Zoumpourlis,A.Pintzas,Highactivityofserum 132. response factor in the mesenchymal transition of epithelial tumor is regulated [47] W. Li, C. Peng, M.H. Lee, D. Lim, F. Zhu, Y. Fu, et al., TRAF4 is a critical molecule by RhoA signaling, J. Biol. Chem. 277 (2002) 29490–29495. for Akt activation in lung cancer, Canc. Res. 73 (2013) 6938–6950.

 [39] K.Katono,Y.Sato,S.Jiang, M.Kobayashi,R.Nagashio,S.Ryuge, etal.,Prognostic [48] X. Fu, C. Liang, F. Li, L. Wang, X. Wu, A. Lu, et al., The rules and functions of significanceofMYH9expressioninresectednon-smallcelllungcancer,PloSOne10 nucleocytoplasmic shuttling proteins, Int. J. Mol. Sci. 19 (2018) 1445. (2015) e0121460. [49] X.H. Wei, S.S. Lin, Y. Liu, R.P. Zhao, G.J. Khan, H.Z. Du, et al., DT-13 attenuates [40] B.Wang,X.Qi,J.Liu,R.Zhou,C.Lin,J.Shangguan,etal.,MYH9promotesgrowth human lung cancer metastasis via regulating NMIIA activity under hypoxia condi- and metastasis via activation of MAPK/AKT signaling in colorectal cancer, J. Canc. tion, Oncol. Rep. 36 (2016) 991–999. 10 (2019) 874–884. [50] R.R. Bowers, Y. Manevich, D.M. Townsend, K.D. Tew, Sulfiredoxin redox-sensitive [41] Y. Liu, Q. Jiang, X. Liu, X. Lin, Z. Tang, C. Liu, et al., Cinobufotalin powerfully interaction with S100A4 and non-muscle myosin IIA regulates cancer cell motility, reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to Biochemistry 51 (2012) 7740–7754. antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3beta/beta-ca- [51] S.S.P. Giridharan, J.L. Rohn, N Talaporfin sodium (ME2906). 

Naslavsky, S. Caplan, Differential regulation of tenin signaling pathway, Ebiomedicine 48 (2019) 386–404. actin microfilaments by human MICAL proteins, J. Cell Sci. 125 (2012) 614–624. [42] B. Zhao, Z. Qi, Y. Li, C. Wang, W. Fu, Y.G. Chen, The non-muscle-myosin-II heavy [52] M. Peckham, How myosin organization of the actin cytoskeleton contributes to the chain Myh9 mediates colitis-induced epithelium injury by restricting Lgr5+ stem cancer phenotype Latrunculin A, Biochem. Soc. Trans. 44 (2016) 1026–1034 cck-8 stability. cells, Nat. Commun. 6 (2015) 7166. [53] V.Betapudi,MyosinIImotorproteinswithdifferentfunctionsdeterminethefateof [43] K. Reville, J.K. Crean, S. Vivers, I. Dransfield, C. Godson, Lipoxin A4 redistributes lamellipodia extension during cell spreading, PloS One 5 (2010) e8560. myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic [54] E.E.Grintsevich,H.G.Yesilyurt,S.K.Rich,R.Hung,J.R.Terman,E.Reisler,F-actin leukocytes, J. Immunol. 176 (2006) 1878–1888. dismantling through a redox-driven synergy between Mical and cofilin, Nat. Cell [44] C. Perez-Ramirez, M. Canadas-Garre, M.A. Molina, M.J. Faus-Dader, M.A. Calleja- Biol. 18 (2016) 876–885. 86

Comments

Post a Comment

Popular posts from this blog

32–44 significance and clinical application prospects

 X.Zhang,etal. Cancer Letters 481 (2020) 32–44 significance and clinical application prospects. purified using a HisTrap HP Ni sepharose (GE Healthcare Life Staphylococcalsuperantigen-likeprotein6(SSL6)isthefirstandthe Sciences, Beijing, China) with the user instructions and identified by only identified bacteria-derived protein that binds CD47 to date ITF2357 (Givinostat) . It has immunoblot with anti-His antibodies. The molecular weight was cal- been reported to promote macrophage phagocytosis by competitively culated by DNASTAR 12.1 software (Woodruff Health Sciences Center binding to CD47 [29]. However, its direct effect on tumor cells is un- Library) according to the amino sequence of His-tag labeled SSL6. clear.SinceCD47canregulatetheproliferationandapoptosisoftumor Recombinant protein was treated with Detoxi-Gel endotoxin removing cells [30 3x FLAG inhibitor ,31], and mediate the tolerance of HCC cells to SFN [13], we gel (Thermo Fisher Scientific, Waltham, MA, USA)
Read more

Contents lists available at ScienceDirect Cancer Letters journal homepage

 Cancer Letters 477 (2020) 107–121 Contents lists available at ScienceDirect Cancer Letters journal homepage: www.elsevier.com/locate/canlet Original Articles Dysbindin promotes pancreatic ductal adenocarcinoma by T activating NF-κB/MDM2 via miR-342–3p a,1 a,1 b,1 c a a a DonglieZhu ,ShiZheng ,ChengFang ,XinGuo ,DandanHan ,MingyaoTang ,HangFu , d e d,∗∗ f,∗∗∗ a,∗ Mingzuo Jiang , Ning Xie , Yongzhan Nie , Xuebiao Yao , Yong Chen a Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi\'an, Shaanxi, 710032, China b Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China c Department of Endoscopic Surgery, 986th Military Hospital, Fourth Military Medical University, Xi\'an, Shaanxi, 710054, China d State Key Laboratory of Cancer Biology 3xFLAG PEPTIDE glpbio , National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical Univer
Read more